Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003142 Mass Balance and Bioavailability Study
NCT07463053Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of JMKX003142 in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Jemincare. Primary endpoints: Mass balance of JMKX003142 at 15 days and Absolute bioavailability of JMKX003142 in plasma at 96 hours. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
JMKX003142
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07463053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463053.